JP2010536929A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536929A5
JP2010536929A5 JP2010522361A JP2010522361A JP2010536929A5 JP 2010536929 A5 JP2010536929 A5 JP 2010536929A5 JP 2010522361 A JP2010522361 A JP 2010522361A JP 2010522361 A JP2010522361 A JP 2010522361A JP 2010536929 A5 JP2010536929 A5 JP 2010536929A5
Authority
JP
Japan
Prior art keywords
eur
ingredients
adjusted
composition
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010522361A
Other languages
English (en)
Japanese (ja)
Other versions
JP5570988B2 (ja
JP2010536929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/061232 external-priority patent/WO2009027437A1/en
Publication of JP2010536929A publication Critical patent/JP2010536929A/ja
Publication of JP2010536929A5 publication Critical patent/JP2010536929A5/ja
Application granted granted Critical
Publication of JP5570988B2 publication Critical patent/JP5570988B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010522361A 2007-08-27 2008-08-27 G−csf結合体の液体調製物 Expired - Fee Related JP5570988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07115047 2007-08-27
EP07115047.8 2007-08-27
PCT/EP2008/061232 WO2009027437A1 (en) 2007-08-27 2008-08-27 Liquid formulation of g-csf conjugate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013229688A Division JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Publications (3)

Publication Number Publication Date
JP2010536929A JP2010536929A (ja) 2010-12-02
JP2010536929A5 true JP2010536929A5 (OSRAM) 2011-04-21
JP5570988B2 JP5570988B2 (ja) 2014-08-13

Family

ID=39862881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010522361A Expired - Fee Related JP5570988B2 (ja) 2007-08-27 2008-08-27 G−csf結合体の液体調製物
JP2013229688A Expired - Fee Related JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013229688A Expired - Fee Related JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Country Status (24)

Country Link
US (1) US8546328B2 (OSRAM)
EP (2) EP2197919B1 (OSRAM)
JP (2) JP5570988B2 (OSRAM)
KR (1) KR20100052501A (OSRAM)
CN (2) CN101827864A (OSRAM)
AU (1) AU2008292186B9 (OSRAM)
BR (1) BRPI0815975B8 (OSRAM)
CA (1) CA2696594C (OSRAM)
CY (1) CY1115908T1 (OSRAM)
DE (1) DE202008017456U1 (OSRAM)
DK (1) DK2197919T3 (OSRAM)
EA (1) EA020069B1 (OSRAM)
ES (1) ES2476915T3 (OSRAM)
HR (1) HRP20140590T1 (OSRAM)
IL (1) IL204190A (OSRAM)
MX (1) MX2010002448A (OSRAM)
NZ (1) NZ583276A (OSRAM)
PL (1) PL2197919T3 (OSRAM)
PT (1) PT2197919E (OSRAM)
RS (1) RS53404B (OSRAM)
SI (1) SI2197919T1 (OSRAM)
UA (1) UA98001C2 (OSRAM)
WO (1) WO2009027437A1 (OSRAM)
ZA (1) ZA201000798B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102740840A (zh) * 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
PL2547699T3 (pl) 2010-03-17 2017-04-28 Ratiopharm Gmbh Sposób otrzymywania biologicznie czynnego rekombinowanego ludzkiego g-csf
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
CN108368512B (zh) * 2016-04-18 2020-03-27 江苏恒瑞医药股份有限公司 一种重组人粒细胞集落刺激因子的制备方法
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
EA202092623A1 (ru) * 2018-05-04 2021-02-01 Илькоген Илач Санайи Ве Тиджарет А.Ш. СТАБИЛЬНЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
CA3262492A1 (en) * 2022-08-19 2024-02-22 Evive Biotechnology (Shanghai) Ltd Formulations containing G-CSF and their uses

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (OSRAM) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US5675941A (en) 1983-12-09 1997-10-14 Dykmans; Maximiliaan J. Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
EP0347041A3 (en) 1988-05-13 1990-11-22 Amgen Inc. Compositions and method for treating or preventing infections in animals
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JPH08502082A (ja) 1992-07-02 1996-03-05 コラーゲン コーポレイション 生体適合性ポリマー結合体
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
IL112583A0 (en) 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
ES2312166T3 (es) 1994-02-23 2009-02-16 Kyowa Hakko Kogyo Co., Ltd Acelerador del crecimiento plaquetario.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1273589C (zh) 1996-02-15 2006-09-06 诺沃奇梅兹有限公司 多肽缀合
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
WO1998055500A1 (en) 1997-06-06 1998-12-10 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CZ20022727A3 (cs) 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
AU2001263149A1 (en) 2000-05-12 2001-11-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
MXPA02011303A (es) 2000-05-15 2003-04-25 Hoffmann La Roche Nueva composicion farmaceutica.
AU2001274853B2 (en) 2000-05-16 2007-03-22 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
ES2466024T3 (es) 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1660134B1 (en) 2003-08-08 2010-12-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and g-csf
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
US20070254836A1 (en) 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
WO2005070138A2 (en) * 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
ES2390885T3 (es) 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
DE102004036909B4 (de) 2004-07-29 2007-04-05 Infineon Technologies Ag Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung
JP4951527B2 (ja) * 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖peg化顆粒球コロニー刺激因子
US20080171857A1 (en) 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
JP5137821B2 (ja) * 2005-06-01 2013-02-06 マキシジェン, インコーポレイテッド Peg化されたg−csfポリペプチドおよびその製造方法
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate

Similar Documents

Publication Publication Date Title
JP2010536929A5 (OSRAM)
JP2009523455A5 (OSRAM)
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
JP2011527560A5 (OSRAM)
EP2589392A3 (en) Process for stabilizing an adjuvant containing vaccine composition
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
JP2013500371A5 (OSRAM)
EP4374878A3 (en) Pharmaceutical composition
TW200635938A (en) Fluorosurfactants
FR2934865B1 (fr) Copolyamide semi-aromatique et son procede de preparation
JP2011510113A5 (OSRAM)
EP3279313A3 (en) Hyperblebbing shigella strains
JP2008188757A5 (OSRAM)
JP2007320968A5 (OSRAM)
JP2006303436A5 (OSRAM)
JP2009249685A5 (OSRAM)
JP2010196033A5 (OSRAM)
JP2010177089A5 (OSRAM)
JP2011511721A5 (OSRAM)
JP2010243737A5 (OSRAM)
JP2011515327A5 (OSRAM)
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
JP2009532412A5 (OSRAM)
JP2012250569A5 (OSRAM)
JP2011059293A5 (OSRAM)